revues

OPEN ACCESS JOURNAL

Gene Section

PRXL2C (Peroxiredoxin like 2C)

Jean Loup Huret

jean-loup.huret@atlasgeneticsoncology.org

Published in Atlas Database: November 2018

Online updated version : http://AtlasGeneticsOncology.org/Genes/PRXL2CID60014ch9q22.html Printable original version : http://documents.irevues.inist.fr/bitstream/handle/2042/70694/11-2018-PRXL2CID60014ch9q22.pdf DOI: 10.4267/2042/70694

This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence. © 2020 Atlas of Genetics and Cytogenetics in Oncology and Haematology

Abstract

Review on PRXL2C, with data on DNA, on the protein encoded, and where the gene is implicated.

Keywords

PRXL2C; oxidation; reduction; Mutation; Overexpression; Cancer; Gastric cancer; Attentiondeficit/hyperactivity disorder

Identity

Other names: C9orf21, AAED1 HGNC (Hugo): AAED1 Location: 9q22.33

DNA/RNA

Description

Six exons, four splice forms, one of which codes for a protein:

Transcription

Coding transcript: 2863bp

Protein

Description

A selenoprotein is a protein containing

selenocysteines (Sec), with an atom of selenium SHE taking the place of the sulfur SH of the cysteine. Decoding of UGA into a selenocysteine (Sec) is alternative to the stop signal in the canonical genetic code.

The human selenoproteins (SelU family) are composed of three Cys-containing members, one of which being PRXL2C (Ensembl ENSG00000158122) (Castellano et al., 2004). PRXL2C amino acids 68-71 are: CYIC, a CXXC motif. According to InterPro http://www.ebi.ac.uk/interpro/protein/Q7RTV5, PRXL2C signature matches with thioredoxin-like superfamily in amino acids 35-135 (or 21-90) (with a thioredoxin CXXC motif at aa 68-71 (CYIC); the two cysteines can forms a disulfide bond), and also matches with peroxiredoxin-like 2A/B/C in aa 86-196 (or 40-150). Peroxiredoxins and thioredoxins involved in oxidation-reduction process are (antioxidants). Peroxiredoxins form a family of thiol oxidoreductases and play a role in peroxides detoxification (see Figure2). A peroxidatic cysteine reduces the peroxide to water. Thioredoxin system reduce peroxiredoxins restoring to them their catalytically active form (West et al., 2018).

Expression

PRXL2C is widely expressed (The Human Protein Atlas).



Figure 1 PRXL2C gene



Peroxides detoxification by Peroxiredoxins motifs -C-X-X-C-

© AtlasGeneticsOncology - Jean Loup Huret 2018

Reproduced from West et al., 2018 PMID:30486489

Figure 2 Peroxides detoxification by Peroxiredoxins motifs -C-X-X-C-

Function

Aaed1 was found to be one of the few primitive endoderm transition markers in preimplantation mouse embryos (Gerovska and Arauzo-Bravo, 2016).

Mutations

Somatic

According to Cosmic

Glioma astrocytoma grade IV amino acid (aa) mutation: p.V91A from CDS mutation c.272T>C Papillary thyroid carcinomas aa mutation p.I81S (c.242T>G)

Thyroid carcinomas NOS aa mutations: p.V95L (c.283G>T); p.G183V (c.548G>T)

Lung small cell carcinoma aa mutation: p.E136K (c.406G>A) (Rudin et al. 2012)

Lung adenocarcinoma aa mutations: p.H145N (c.433C>A) (Imielinski et al. 2012); p.S152L (c.455C>T)

Skin melanoma aa mutations: p.M131I (c.393G>A); p.S148L (c.443C>T); p.W159* (c.476G>A)

Colon adenocarcinoma aa mutations: p.E76D (c.228G>T); p.L110Q (c.329T>A) (Giannakis et al. 2016); p.S143I (c.428G>T) (Giannakis et al. 2016); p.Q208H (c.624G>T) (Wood et al. 2007); p.P221H (c.662C>A)

Duodenum adenoma aa mutations: p.K201N (c.603A>C) (Yachida et al. 2016); p.T218A (c.652A>G) (Yachida et al. 2016)

Prostate adenocarcinoma aa mutation: p.H214R (c.641A>G)

Implicated in

Gastric cancer

(AhpC/TSA antioxidant enzyme domain containing 1), which is upregulated in gastric

cancer cells. Silencing of PRXL2C inhibited cancer cell proliferation in vitro in gastric cancer cell lines. Possibly though MAPK signaling, PRXL2C upregulates HIF1A (hypoxia inducible factor 1 subunit alpha), a transcriptional activator of many genes, including glycolytic enzymes and glucose transporters in aerobic glycolysis (Zhang et al., 2018).

Renal cancer

PRXL2C High expression is related with an unfavourable prognosis according to the Human Protein Atlas

https://www.proteinatlas.org/ENSG00000158122-AAED1/pathology

Attention-deficit/hyperactivity disorder (ADHD)

A rare variant of PRXL2C (rs151326868) amino acid p.H200D (c.598C>G) was found to segregate with ADHD in one of the families with an apparent dominant inheritance that was studied (Corominas et al., 2018).

PRXL2C binds PICK1 (Protein Kinase C-Alpha-Binding Protein) and PICK1 binds SLC6A3 (solute carrier family 6 member 3, also known as DAT, the dopamine transporter 1), regulating SLC6A3 trafficking in presynaptic sites of dopaminergic neurons, and DRD3 (dopamine D3 receptor 3). PICK1 also has a role in glutamate receptor regulation (Corominas et al., 2018).

Disease

ADHD is characterized by of lack of attention, impulsivity, hyperactivity and distractibility.

It is a highly heritable (80%-90%) childhood behavioral disorder with a prevalence estimated at 5-7% in children, male predominance, and half of them have persisting symptoms in adulthood.

In addition to genetic factors, environmental factors (adverse circumstances in maternal or children life) have been implicated in the etiology of ADHD.

References

Castellano S, Novoselov SV, Kryukov GV, Lescure A, Blanco E, Krol A, Gladyshev VN, Guigó R. Reconsidering the evolution of eukaryotic selenoproteins: a novel nonmammalian family with scattered phylogenetic distribution. EMBO Rep. 2004 Jan;5(1):71-7

Corominas J, Klein M, Zayats T, Rivero O, Ziegler GC, Pauper M, Neveling K, Poelmans G, Jansch C, Svirin E, Geissler J, Weber H, Reif A, Arias Vasquez A, Galesloot TE, Kiemeney LALM, Buitelaar JK, Ramos-Quiroga JA, Cormand B, Ribasés M, Hveem K, Gabrielsen ME, Hoffmann P, Cichon S, Haavik J, Johansson S, Jacob CP, Romanos M, Franke B, Lesch KP. Identification of ADHD risk genes in extended pedigrees by combining linkage analysis and whole-exome sequencing. Mol Psychiatry. 2018 Aug 16;

Gerovska D, Araúzo-Bravo MJ. Does mouse embryo primordial germ cell activation start before implantation as suggested by single-cell transcriptomics dynamics? Mol Hum Reprod. 2016 Mar;22(3):208-25

Giannakis M, Mu XJ, Shukla SA, Qian ZR, Cohen O, Nishihara R, Bahl S, Cao Y, Amin-Mansour A, Yamauchi M, Sukawa Y, Stewart C, Rosenberg M, Mima K, Inamura K, Nosho K, Nowak JA, Lawrence MS, Giovannucci EL, Chan AT, Ng K, Meyerhardt JA, Van Allen EM, Getz G, Gabriel SB, Lander ES, Wu CJ, Fuchs CS, Ogino S, Garraway LA. Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma. Cell Rep. 2016 Apr 26;15(4):857-865

Imielinski M, Berger AH, Hammerman PS, Hernandez B, Pugh TJ, Hodis E, Cho J, Suh J, Capelletti M, Sivachenko A, Sougnez C, Auclair D, Lawrence MS, Stojanov P, Cibulskis K, Choi K, de Waal L, Sharifnia T, Brooks A, Greulich H, Banerji S, Zander T, Seidel D, Leenders F, Ansén S, Ludwig C, Engel-Riedel W, Stoelben E, Wolf J, Goparju C, Thompson K, Winckler W, Kwiatkowski D, Johnson BE, Jänne PA, Miller VA, Pao W, Travis WD, Pass HI, Gabriel SB, Lander ES, Thomas RK, Garraway LA, Getz G, Meyerson M. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing Cell 2012 Sep 14;150(6):1107-20

Rudin CM, Durinck S, Stawiski EW, Poirier JT, Modrusan

Z, Shames DS, Bergbower EA, Guan Y, Shin J, Guillory J, Rivers CS, Foo CK, Bhatt D, Stinson J, Gnad F, Haverty PM, Gentleman R, Chaudhuri S, Janakiraman V, Jaiswal BS, Parikh C, Yuan W, Zhang Z, Koeppen H, Wu TD, Stern HM, Yauch RL, Huffman KE, Paskulin DD, Illei PB, Varella-Garcia M, Gazdar AF, de Sauvage FJ, Bourgon R, Minna JD, Brock MV, Seshagiri S. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer Nat Genet 2012 Oct;44(10):1111-6

West JD, Roston TJ, David JB, Allan KM, Loberg MA. Piecing Together How Peroxiredoxins Maintain Genomic Stability Antioxidants (Basel) 2018 Nov 28;7(12)

Wood LD, Parsons DW, Jones S, Lin J, Sjöblom T, Leary RJ, Shen D, Boca SM, Barber T, Ptak J, Silliman N, Szabo S, Dezso Z, Ustyanksky V, Nikolskaya T, Nikolsky Y, Karchin R, Wilson PA, Kaminker JS, Zhang Z, Croshaw R, Willis J, Dawson D, Shipitsin M, Willson JK, Sukumar S, Polyak K, Park BH, Pethiyagoda CL, Pant PV, Ballinger DG, Sparks AB, Hartigan J, Smith DR, Suh E, Papadopoulos N, Buckhaults P, Markowitz SD, Parmigiani G, Kinzler KW, Velculescu VE, Vogelstein B. The genomic landscapes of human breast and colorectal cancers Science 2007 Nov 16;318(5853):1108-13

Yachida S, Wood LD, Suzuki M, Takai E, Totoki Y, Kato M, Luchini C, Arai Y, Nakamura H, Hama N, Elzawahry A, Hosoda F, Shirota T, Morimoto N, Hori K, Funazaki J, Tanaka H, Morizane C, Okusaka T, Nara S, Shimada K, Hiraoka N, Taniguchi H, Higuchi R, Oshima M, Okano K, Hirono S, Mizuma M, Arihiro K, Yamamoto M, Unno M, Yamaue H, Weiss MJ, Wolfgang CL, Furukawa T, Nakagama H, Vogelstein B, Kiyono T, Hruban RH, Shibata T. Genomic Sequencing Identifies ELF3 as a Driver of Ampullary Carcinoma Cancer Cell 2016 Feb 8;29(2):229-40

Zhang B, Wu J, Cai Y, Luo M, Wang B, Gu Y. AAED1 modulates proliferation and glycolysis in gastric cancer Oncol Rep 2018 Aug;40(2):1156-1164

This article should be referenced as such:

Huret JL. PRXL2C (Peroxiredoxin like 2C). Atlas Genet Cytogenet Oncol Haematol. 2020; 24(4):156-158.